Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: Effect of interventions on outcome

被引:25
作者
Bethge, WA
Storer, BE
Maris, MB
Flowers, MED
Maloney, DG
Chauncey, TR
Woolfrey, AE
Storb, R
Sandmaier, BM
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Vet Affairs Med Ctr, Seattle, WA 98108 USA
关键词
D O I
10.1016/S0301-472X(03)00225-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. This study analyzes the effect of interventions aimed at reinducing remissions in patients with relapse or progression of malignant disease following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative conditioning. Methods. We performed a retrospective analysis of 81 instances of relapse or progression occurring among 224 patients given HCT as treatment of their hematologic malignancies. All patients received conditioning with 2 Gy total-body irradiation with or without fludarabine and with postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Results. Overall survival of patients after relapse or progression was 36%. Fifteen of the 81 patients were given no interventions. Three of these 15 (20%) patients are alive with disease while 12 died with disease progression. Sixty-six patients (81%) received interventions, including withdrawal of immunosuppression (n = 32), donor lymphocyte infusions (n = 13), or chemotherapy (n = 21). Twenty of the 66 (30%) are alive, 5 in complete remission, 4 in partial remission, I with stable and 10 with progressive disease. The overall response rate to intervention was 27%. Forty-six (70%) of the patients given interventions died, mainly due to relapse/progression. Patients not receiving interventions had a I-year survival estimate of 15% compared to 41% in patients given interventions. Factors associated with survival in patients given intervention were disease response (p = 0.002), disease category (p = 0.001), and time to relapse from transplantation (p = 0.0005). Conclusion. While the overall prognosis of patients relapsing or progressing after nonmyeloablative HCT is poor, interventions such as the combined use of immunotherapy and chemotherapy can improve patient survival. (C) 2003 International Society-for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:974 / 980
页数:7
相关论文
共 32 条
[1]  
[Anonymous], 1999, Hematopoietic stem cell transplantation
[2]   Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation [J].
Baurmann, H ;
Nagel, S ;
Binder, T ;
Neubauer, A ;
Siegert, V ;
Huhn, D .
BLOOD, 1998, 92 (10) :3582-3590
[3]   Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation [J].
Bjorkstrand, B ;
Ljungman, P ;
Svensson, H ;
Hermans, J ;
Alegre, A ;
Apperley, J ;
Blade, J ;
Carlson, K ;
Cavo, M ;
Ferrant, A ;
Goldstone, AH ;
deLaurenzi, A ;
Majolino, I ;
Marcus, R ;
Prentice, HG ;
Remes, K ;
Samson, D ;
Sureda, A ;
Verdonck, LF ;
Volin, L ;
Gahrton, G .
BLOOD, 1996, 88 (12) :4711-4718
[4]   Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation [J].
Brandenburg, U ;
Gottlieb, D ;
Bradstock, K .
LEUKEMIA & LYMPHOMA, 1998, 31 (5-6) :545-550
[5]  
BRYANT E, 1999, HEMATOPOIETIC CELL T, P197
[6]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[7]   Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [J].
de Witte, T ;
Hermans, J ;
Vossen, J ;
Bacigalupo, A ;
Meloni, G ;
Jacobsen, N ;
Ruutu, T ;
Ljungman, P ;
Gratwohl, A ;
Runde, V ;
Niederwieser, D ;
van Biezen, A ;
Devergie, A ;
Cornelissen, J ;
Jouet, JP ;
Arnold, R ;
Apperley, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :620-630
[8]   Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant [J].
Feinstein, LC ;
Sandmaier, BM ;
Maloney, DG ;
Maris, MB ;
Gooley, TA ;
Chauncey, TR ;
Hegenbart, U ;
McSweeney, PA ;
Stuart, MJ ;
Forman, SJ ;
Agura, EA ;
Pulsipher, MA ;
Blume, KG ;
Niedervieser, DW ;
Storb, RF .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (04) :266-272
[9]   Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission [J].
Feinstein, LC ;
Sandmaier, BM ;
Hegenbart, U ;
McSweeney, PA ;
Maloney, DG ;
Gooley, TA ;
Maris, MB ;
Chauncey, TR ;
Bruno, B ;
Appelbaum, FR ;
Niederwieser, DW ;
Storb, RF .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :281-288
[10]  
Kalbfleisch J.D., 1980, The statistical analysis of failure time data